DETECTION OF CMV INFECTIONS IN AIDS PATIENTS IN CLINICAL PROTOCOLS

由于CMV被认为是主要的机会性感染之一 对于艾滋病患者，监测血液、尿液和组织是很重要的 来自参加各种临床试验的患者的样本 出现巨细胞病毒。以下临床方案目前正在进行中 进度： (1)抗HIV-1的联合疗法：AZT/IL2、干扰素-α/IL2和 AZT、干扰素和AZT/干扰素联合应用的三臂试验此外，我们 正在跟踪一小群同卵双胞胎(只有一个是HIV-1 已接受自体骨髓移植的患者)。 (2)这个项目的另一个目标是确定是否可以分离出CMV 从无症状的和无症状的 有症状的HIV-1患者。它可能会提供早期的指标 在这些患者中重新激活CMV，并导致早期启动抗- 预防全身性暴发性疾病的巨细胞病毒治疗。 (3)磷甲酸三钠的临床试验 用于治疗患有巨细胞病毒视网膜炎的HIV-1患者。改进的是 通过减少从组织样本中分离CMV来记录， 改善视力，降低HIV-1p24水平。 (4)随机、双盲、对照试验 巨细胞病毒免疫球蛋白预防巨细胞病毒感染的疗效观察 艾滋病患者。

Since CMV is recognized as one of the leading opportunistic infections in AIDS patients, it is important to monitor blood, urine, and tissue specimens from patients enrolled in various clinical trials for the presence of CMV. The following clinical protocols are currently in progress: (1) Combination therapies against HIV-1 : AZT/IL2, IFN-alpha /IL2, and a three arm trial of combination AZT, IFN, and AZT/IFN. In addition, we are following a small group of identical twins (only one is HIV-1 infected) who have undergone autologous bone marrow transplantation. (2) Another goal of this project is to determine if CMV can be isolated from bronchial lavage specimens taken from asymptomatic as well as symptomatic HIV-1 patients. It may provide an early indicator of reactivated CMV in these patients, and lead to early initiation of anti- CMV treatment to prevent systemic fulminating disease. (3) Clinical trial with the drug foscarnet (trisodium phosphonoformate) for the treatment of HIV-1 patients with CMV retinitis. Improvement was documented by a reduction of CMV isolation from tissue specimens, improved vision, and reduced HIV-1 p24 levels. (4) A randomized, double blind, controlled trial to determine the efficacy of CMV-immuneglobulins for prophylaxis of CMV infections in AIDS patients.